top of page
News
April 9, 2024
FuseBio Presents New Data at AACR: Targeting a Functionally-selective IL-18 (F-18) to PD-1: A Next Generation Checkpoint Inhibitor with Enhanced Anti-tumor Activity
November 5, 2022
FuseBio Presents New Data at SITC: A ROR1 specific cell engager engineered for solid tumors with an expanded therapeutic window
November 15, 2021
Fuse Biotherapeutics Raises an Oversubscribed and Upsized Seed Financing Round of $9.5 Million
bottom of page